Table 1.
Clinical characteristics in HCC patients with AHSA1-high expression or AHSA1-low expression in TCGA-LIHC database.
| Clinical Characteristics | AHSA1-Low Group (n = 172) | AHSA1-High Group (n = 172) |
|---|---|---|
| Survival status | ||
| Alive | 124 (72.1%) | 105 (61.0%) |
| Dead | 48 (27.9%) | 67 (40.0%) |
| Disease-Free Status | ||
| Disease-Free | 74 (43.0%) | 63 (81.8%) |
| Recurred/Progressed | 81 (47.1%) | 81 (50.6%) |
| NA | 17 (9.9%) | 28 (16.3%) |
| Age | ||
| ≤65 | 70 (40.7%) | 57 (33.1%) |
| >65 | 102 (59.3%) | 115 (66.9%) |
| Gender | ||
| MALE | 110 (64.0%) | 122 (70.9%) |
| FEMALE | 62 (36.0%) | 50 (29.1%) |
| Grade | ||
| G1-G2 | 113 (65.7%) | 100 (58.1%) |
| G3-G4 | 56 (32.6%) | 70 (40.7%) |
| unknow | 3 (1.7%) | 2 (1.2%) |
| TNM Stage | ||
| Stage I–II | 126 (73.3%) | 112 (65.1%) |
| Stage III–IV | 35 (20.3%) | 50 (29.1%) |
| unknow | 11 (6.4%) | 10 (5.8%) |
| T Stage | ||
| T1-2 | 133 (77.3%) | 121 (70.3%) |
| T3-4 | 37 (22.1%) | 50 (29.1%) |
| TX | 2 (1.2%) | 1 (0.6%) |
| M stage | ||
| M0 | 120 (69.8%) | 127 (73.8%) |
| M1 | 2 (1.2%) | 2 (1.2%) |
| MX | 50 (34.3%) | 43 (25.0%) |
| N stage | ||
| N0 | 111 (64.5%) | 123 (71.5%) |
| N1 | 2 (1.2%) | 1 (0.6%) |
| NX | 59 (34.3%) | 48 (27.9%) |
| AFP level | ||
| <400 | 113 (65.7%) | 86 (50.5%) |
| ≥400 | 26 (15.1%) | 34 (19.8%) |
| NA | 33 (19.2%) | 52 (30.2%) |
| Vascular Invasion | ||
| Yes | 45 (26.2%) | 52 (30.3%) |
| None | 107 (62.2%) | 85 (49.4%) |
| NA | 20 (11.6%) | 35 (20.3%) |
NA, Not Available; AFP, Alpha fetoprotein.